

7 April 2026

**ImmuPharma PLC**  
**("ImmuPharma" or the "Company")**

**Result of General Meeting and TVR**

**Resolutions Approved**

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that both resolutions proposed at the General meeting held earlier today were approved by Shareholders.

This is further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the "**Fundraising RNS**") and the WRAP Retail Offer announcement published on 17 March 2026 at 7:01 a.m. (the "**WRAP RNS**"),

Details of the voting are as set out below:

<b>ORDINARY RESOLUTION</b>	For	% For	Against	% Against	Withheld
1. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting	77,375,610	91.46%	7,228,476	8.54%	1,056,465
<b>SPECIAL RESOLUTION</b> 2. That, subject to the passing of Resolution 1 the directors be and they are hereby empowered pursuant to section 570 of the Act to allot equity securities as set out in the Notice of Meeting	75,221,313	88.91%	9,378,404	11.09%	1,060,834

**Allotment of Shares**

At a Board meeting held following the General Meeting, 100,000,000 Subscription Shares, 12,000,000 Value Payment Shares, 7,812,447 WRAP Retail Offer Shares and 1,375,000 Fee Shares (together the "New Ordinary Shares") have been allotted.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to occur at 8.00 a.m. on 8 April 2026.

**Total Voting Rights**

Upon admission of the New Ordinary Shares, the Company's issued ordinary share capital will comprise 623,911,379 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. This figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

All New Ordinary Shares have been issued free of all liens, charges and encumbrances and will, from Admission, rank *pari passu* in all respects with the Company's existing Ordinary Shares.

**Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS and / or WRAP RNS.**

**For further information, please contact:**

<b>ImmuPharma PLC (<a href="http://www.immupharma.co.uk">www.immupharma.co.uk</a>)</b>	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	
<b>Stanford Capital Partners (Joint Broker)</b>	44 (0) 20 3650 3650
Patrick Claridge, Bob Pountney	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.